Abstract B077: FOLFIRINOX Bolsters the Intratumoral and Systemic B Cell Activation Compared to Gemcitabine-Abraxane in Patients with PDAC
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer related deaths in the world, and its poor prognosis is driven by an immunosuppressive tumor microenvironment (TME). Standard PDAC treatment combines surgical resection with perioperative chemotherapy, either Gemcitabine-Abraxane (Gem) or FOL...